Skip to main content

GlaxoSmithKline

 

Clinical courses

  • ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced it has agreed to purchase Bristol-Myers Squibb’s late stage HIV R&D assets. In a separate deal, ViiV Healthcare has agreed to acquire Bristol-Myers Squibb’s HIV portfolio of pre-clinical and discovery stage research assets. Each deal is subject to clearance by the regulatory authorities and is expected to complete in early 2016.

  • GlaxoSmithKline plc  received approval from the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for Nucala® (mepolizumab) as an add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. Nucala is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.

  • GSK and Merck, known as MSD outside the US and Canada, announced the initiation of a phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and  in combination with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment.

  • Job as Medical Representatives in GlaxoSmithKline

    Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3500 people. Globally, we are a £ 26.4 billion, leading, research-based healthcare and pharmaceutical company. In India, we are one of the market leaders with a turnover of Rs. 3021 crore and a share of 4.2%*. At GSK, our mission is to improve the quality of life by enabling people to do more, feel better and live longer. This mission drives us to make a real difference to the lives of millions of people with our commitment to effective healthcare solutions.

    Post: Medical Representatives

  • Career in GlaxoSmithKline as Assistant Manager Regulatory Affairs

    Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3500 people. Globally, we are a £ 26.4 billion, leading, research-based healthcare and pharmaceutical company. In India, we are one of the market leaders with a turnover of Rs. 3021 crore and a share of 4.2%*. At GSK, our mission is to improve the quality of life by enabling people to do more, feel better and live longer.

  • Vacancy for Asst. Manager - Manufacturing in GlaxoSmithKline

    GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 4000 people. Globally, we are a £ 27.4 billion, leading, research-based healthcare and pharmaceutical company. In India, we are one of the market leaders. At GSK, our mission is to improve the quality of life by enabling people to do more, feel better and live longer.

  • Walk-in-Interview: Job as Study Coordinator & Research Assistant at National Institute of Nutrition - 3 Vacancies

    National Institute of Nutrition (NIN) was founded by Sir Robert McCarrison in the year 1918 as ‘Beri-Beri’ Enquiry Unit in a single room laboratory at the Pasteur Institute, Coonoor, Tamil Nadu. Within a short span of seven years, this unit blossomed into a "Deficiency Disease Enquiry" and later in 1928, emerged as full-fledged "Nutrition Research Laboratories" (NRL) with Dr. McCarrison as its first Director. It was shifted to Hyderabad in 1958.

  • GSK gets clean chit from DCGI for running cervical cancer vaccine ads in media

    The multinational drug company GlaxoSmithKline (GSK), which had run an advertisement blitzkrieg in several national newspapers in the country on cervical cancer vaccine late last year in gross violation of Drugs and Cosmetics Act, 1940 and Drugs and Magical Remedies Act 1954, has been completely absolved of any irregularities by the drug controller general of India (DCGI) Dr Surinder Singh, it is learnt.

  • Liraglutide Superior to Sitagliptin When Added to Metformin for Glycemic Control

    The addition of a glucagonlike peptide-1 (GLP-1) agonist in patients with inadequate glycemic control when treated with metformin alone resulted in significantly larger reductions in HbA1c levels when compared with the addition of a dipeptidyl peptidase-4 (DPP-4) inhibitor, a new study has shown.

Subscribe to GlaxoSmithKline